SCHEDULE 13D/A: Key Shareholder Einodmil LLC Reduces Stake in OS Therapies Inc Through Recent Stock Sales

Einodmil LLC, a significant beneficial owner of OS Therapies Inc, has reported the sale of 142,012 shares of common stock in April and May 2025, reducing its stake to 9.8%.

Summary

• This filing is Amendment No. 3 to the Schedule 13D, updating beneficial ownership information for OS Therapies Inc.
• Reporting person Einodmil LLC sold a total of 142,012 shares of OS Therapies Inc common stock across three separate transactions in April and May 2025.
• On May 7, 2025, Einodmil LLC sold 82,000 shares at a weighted average price of approximately $1.9986 per share, generating proceeds of approximately $163,885.
• On April 10, 2025, Einodmil LLC sold 10,000 shares at a weighted average price of approximately $1.39 per share, generating proceeds of approximately $13,900.
• On April 9, 2025, Einodmil LLC sold 50,012 shares at a weighted average price of approximately $1.353 per share, generating proceeds of approximately $67,700.
• As of the filing date, Shalom Auerbach beneficially owns 2,687,570 shares, representing approximately 9.9% of the Issuer's outstanding common stock.
• As of the filing date, Einodmil LLC beneficially owns 2,664,199 shares, representing approximately 9.8% of the Issuer's outstanding common stock.
• The total number of OS Therapies Inc common shares outstanding is reported as 27,202,661.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to significant insider selling, which can be interpreted by the market as a lack of confidence or a strategic divestment by a key beneficial owner. However, the filing itself is purely factual and does not contain negative language.

Negatives

• Significant sales by a beneficial owner (Einodmil LLC) may be perceived negatively by the market, potentially signaling a lack of confidence or a need for liquidity from the seller's perspective.
• The sales occurred at varying price points, with the largest sale on May 7, 2025, at a higher price ($1.9986) compared to the April sales ($1.39 and $1.353), indicating the seller capitalized on a price increase.

Risks

• The document does not explicitly state new risks for OS Therapies Inc, but significant insider selling can be interpreted by investors as a potential risk factor regarding future stock performance or internal outlook.

Future Outlook

NA

Industry Context

This Schedule 13D amendment primarily reports changes in beneficial ownership by a significant shareholder and does not provide information related to broader industry trends or competitive landscape for OS Therapies Inc.

Related Party Transactions

• The filing references a Transfer Agreement dated May 13, 2024, by and between Einodmil and Paul Romness, incorporated by reference as Exhibit 2 to the original Schedule 13D. No new related party transactions are detailed in this amendment.

Stakeholder Impact

• Shareholders may interpret the sales by a significant beneficial owner as a negative signal regarding the company's near-term prospects or valuation, potentially leading to downward pressure on the stock price.

Key Dates

Keywords

OS Therapies Inc, Schedule 13D, beneficial ownership, insider selling, common stock, stock sales, Shalom Auerbach, Einodmil LLC, SEC filing